Nöromüsküler Kavşak Hastalıkları: Klinik, İmmünolojik ve Güncel Tedavi Yaklaşımları

Sieb JP. Myasthenia gravis: an update for the clinician. Clin Exp Immunol. 2014 Mar;175(3):408-18. doi: 10.1111/cei.12217. PMID: 24117026; PMCID: PMC3927901.

Nacu A, Andersen JB, Lisnic V, et al. Complicating autoimmune diseases in myasthenia gravis: a review. Autoimmunity. 2015;48(6):362-8. doi: 10.3109/08916934.2015.1030614. Epub 2015 Apr 27. PMID: 25915571; PMCID: PMC4616023.

Gilhus NE. Myasthenia Gravis. N Engl J Med. 2017 Mar 30;376(13):e25. doi: 10.1056/NEJMc1701027. PMID: 28355508.

Mazzoli M, Ariatti A, Valzania F, et al. Factors affecting outcome in ocular myasthenia gravis. Int J Neurosci. 2018 Jan;128(1):15-24. doi: 10.1080/00207454.2017.1344237. Epub 2017 Jul 17. PMID: 28625092.

Ciafaloni E. Myasthenia Gravis and Congenital Myasthenic Syndromes. Continuum (Minneap Minn). 2019 Dec;25(6):1767-1784. doi: 10.1212/CON.0000000000000800. PMID: 31794470.

Bodkin C, Pascuzzi RM. Update in the Management of Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome. Neurol Clin. 2021 Feb;39(1):133-146. doi: 10.1016/j.ncl.

2020.09.007. Epub 2020 Nov 7. PMID: 33223079.

Kesner VG, Oh SJ, Dimachkie MM, et al. Lambert-Eaton Myasthenic Syndrome. Neurol Clin. 2018 May;36(2):379-394. doi: 10.1016/j.ncl.2018.01.008. PMID: 29655456; PMCID: PMC6690495.

Rao AK, Sobel J, Chatham-Stephens K, et al. Clinical Guidelines for Diagnosis and Treatment of Botulism, 2021. MMWR Recomm Rep. 2021 May 7;70(2):1-30. doi: 10.15585/mmwr.rr7002a1. PMID: 33956777; PMCID: PMC8112830.

Özer Çelik A, Şengün İŞ. Botulismus. Tanrıdağ T, editör. Nöromusküler Kavşak Hastalıkları. 1. Baskı. Ankara: Türkiye Klinikleri; 2019. p.50-4.

Ayşe WILLKE Turkiye Klinikleri J Int Med Sci. 2006;2(28):106-12

Shieh PB, Oh SJ. Congenital Myasthenic Syndromes. Neurol Clin. 2018 May;36(2):367-378. doi: 10.1016/j.ncl.2018.01.007. PMID: 29655455.

Finsterer J. Congenital myasthenic syndromes. Orphanet J Rare Dis. 2019 Feb 26;14(1):

57. doi: 10.1186/s13023-019-1025-5. PMID: 30808424; PMCID: PMC6390566.

Sonkar KK, Bhoi SK, Dubey D, et al. Direct and indirect cost of myasthenia gravis: A prospective study from a tertiary care teaching hospital in India. J Clin Neurosci. 2017 Apr;38:114-117. doi: 10.1016/j.jocn.2016.11.003. Epub 2016 Nov 23. PMID: 27887977.

Alshekhlee A, Miles JD, Katirji B, et al. Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals. Neurology. 2009 May 5;72(18):1548-54. doi: 10.1212/WNL.0b013e3181a41211. PMID: 19414721.

Wang S, Breskovska I, Gandhy S, et al. Advances in autoimmune myasthenia gravis management. Expert Rev Neurother. 2018 Jul;18(7):573-588. doi: 10.1080/14737175.2018.1491310. Epub 2018 Jul 4. PMID: 29932785; PMCID: PMC6289049.

Nalbantoğlu M, Adatepe N. Miyastenia Gravis ve Diğer Nöromusküler İleti Bozukluğu Hastalıkları., Balcı Eraslan A (Ed.), Mediasten Hastalıkları ve Cerrahisi içinde. Türkiye Solunum Araştırmaları Derneği; Ağustos 2015. p.229-243

Drachman DB, Kaminski HJ. Neuromuscular junction as Achilles' heel: yet another autoantibody? Neurology. 2014 Jun 3;82(22):1942-3. doi: 10.1212/WNL.

0000000000000486. Epub 2014 May 2. PMID: 24793186.

Kusner LL, Sengupta M, Kaminski HJ. Acetylcholine receptor antibody-mediated animal models of myasthenia gravis and the role of complement. Ann N Y Acad Sci. 2018 Feb;1413(1):136-142. doi: 10.1111/nyas.13555. Epub 2018 Jan 21. PMID: 29356015.

Howard JF Jr. Myasthenia gravis: the role of complement at the neuromuscular junction. Ann N Y Acad Sci. 2018 Jan;1412(1):113-128. doi: 10.1111/nyas.13522. Epub 2017 Dec 21. PMID: 29266249.

Loutrari H, Kokla A, Tzartos SJ. Passive transfer of experimental myasthenia gravis via antigenic modulation of acetylcholine receptor. Eur J Immunol. 1992 Sep;22(9):2449-52. doi: 10.1002/eji.1830220939. PMID: 1516631.

Hara H, Hayashi K, Ohta K, et al. Detection and characterization of blocking-type anti-acetylcholine receptor antibodies in sera from patients with myasthenia gravis. Clin Chem. 1993 Oct;39(10):2053-7. PMID: 8403390.

Sanders DB, Burns TM, Cutter GR, et al. Muscle Study Group. Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis? Muscle Nerve. 2014 Apr;49(4):483-6. doi: 10.1002/mus.23944. PMID: 23835683.

Hoch W, McConville J, Helms S, et al. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med. 2001 Mar;7(3):365-8. doi: 10.1038/85520. PMID: 11231638.

Punga AR, Lin S, Oliveri F, et al. Muscle-selective synaptic disassembly and reorganization in MuSK antibody positive MG mice. Exp Neurol. 2011 Aug;230(2):207-17. doi: 10.1016/j.expneurol.2011.04.018. Epub 2011 Apr 30. PMID: 21565192.

Klooster R, Plomp JJ, Huijbers MG, et al. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. Brain. 2012 Apr;135(Pt 4):1081-101. doi: 10.1093/brain/aws025. Epub 2012 Mar 6. PMID: 22396395.

Messéant J, Dobbertin A, Girard E, et al. MuSK frizzled-like domain is critical for mammalian neuromuscular junction formation and maintenance. J Neurosci. 2015 Mar 25;35(12):4926-41. doi: 10.1523/JNEUROSCI.3381-14.2015. PMID: 25810523; PMCID: PMC6705368.

Plomp JJ, Huijbers MG, van der Maarel SM, et al. Pathogenic IgG4 subclass autoantibodies in MuSK myasthenia gravis. Ann N Y Acad Sci. 2012 Dec;1275:114-22. doi: 10.1111/j.1749-6632.2012.06808.x. PMID: 23278586.

Huijbers MG, Vink AF, Niks EH, et al. Longitudinal epitope mapping in MuSK myasthenia gravis: implications for disease severity. J Neuroimmunol. 2016 Feb 15;291:82-8. doi: 10.1016/j.jneuroim.2015.12.016. Epub 2016 Jan 5. PMID: 26857500.

Deymeer F, Gungor-Tuncer O, Yilmaz V, et al. Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis. Neurology. 2007 Feb 20;68(8):609-11. doi: 10.1212/01.wnl.0000254620.45529.97. PMID: 17310034.

Zisimopoulou P, Evangelakou P, Tzartos J, et al. A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. J Autoimmun. 2014 Aug;52:139-45. doi: 10.1016/j.jaut.2013.12.004. Epub 2013 Dec 24. PMID: 24373505.

Tzartos JS, Zisimopoulou P, Rentzos M, et al. LRP4 antibodies in serum and CSF from amyotrophic lateral sclerosis patients. Ann Clin Transl Neurol. 2014 Feb;1(2):80-7. doi: 10.1002/acn3.26. Epub 2013 Dec 30. PMID: 25356387; PMCID: PMC4212481.

Shen C, Lu Y, Zhang B,et al. Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis. J Clin Invest. 2013 Dec;123(12):5190-202. doi: 10.1172/JCI66039. Epub 2013 Nov 8. PMID: 24200689; PMCID: PMC3859418.

Li Y, Zhang Y, Cai G, et al. Anti-LRP4 autoantibodies in Chinese patients with myasthenia gravis. Muscle Nerve. 2017 Nov;56(5):938-942. doi: 10.1002/mus.25591. Epub 2017 Apr 8. PMID: 28120340.

Higuchi O, Hamuro J, Motomura M, et al. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol. 2011 Feb;69(2):418-22. doi: 10.1002/ana.22312. PMID: 21387385.

Pevzner A, Schoser B, Peters K, et al. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. J Neurol. 2012 Mar;259(3):427-35. doi: 10.1007/

s00415-011-6194-7. Epub 2011 Aug 5. PMID: 21814823.

Zhang B, Tzartos JS, Belimezi M, et al. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol. 2012 Apr;69(4):445-51. doi: 10.1001/archneurol.2011.2393. Epub 2011 Dec 12. PMID: 22158716.

Gilhus NE, Skeie GO, Romi F, et al. Myasthenia gravis - autoantibody characteristics and their implications for therapy. Nat Rev Neurol. 2016 May;12(5):259-68. doi: 10.1038/

nrneurol.2016.44. Epub 2016 Apr 22. PMID: 27103470.

Romi F, Hong Y, Gilhus NE. Pathophysiology and immunological profile of myasthenia gravis and its subgroups. Curr Opin Immunol. 2017 Dec;49:9-13. doi: 10.1016/j.coi.

2017.07.006. Epub 2017 Aug 4. PMID: 28780294.

Marx A, Willcox N, Leite MI, et al. Thymoma and paraneoplastic myasthenia gravis. Autoimmunity. 2010 Aug;43(5-6):413-27. doi: 10.3109/08916930903555935. PMID: 20380583.

Vrolix K, Fraussen J, Molenaar PC, et al. The auto-antigen repertoire in myasthenia gravis. Autoimmunity. 2010 Aug;43(5-6):380-400. doi: 10.3109/08916930903518073. PMID: 20380581.

Leite MI, Jacob S, Viegas S, et al. IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain. 2008 Jul;131(Pt 7):1940-52. doi: 10.1093/brain

/awn092. Epub 2008 May 31. PMID: 18515870; PMCID: PMC2442426.

Tüzün E, Christadoss P. Complement associated pathogenic mechanisms in myasthenia gravis. Autoimmun Rev. 2013 Jul;12(9):904-11. doi: 10.1016/j.autrev.2013.03.003. Epub 2013 Mar 26. PMID: 23537510.

Gomez AM, Van Den Broeck J, Vrolix K, et al. Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction. Autoimmunity. 2010 Aug;43(5-6):353-70. doi: 10.3109/08916930903555943. PMID: 20380584.

Marx A, Pfister F, Schalke B, et al. The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes. Autoimmun Rev. 2013 Jul;12(9):875-84. doi: 10.1016/j.autrev.2013.03.007. Epub 2013 Mar 25. PMID: 23535159.

Truffault F, de Montpreville V, Eymard B, et al. Thymic Germinal Centers and Corticosteroids in Myasthenia Gravis: an Immunopathological Study in 1035 Cases and a Critical Review. Clin Rev Allergy Immunol. 2017 Feb;52(1):108-124. doi: 10.1007/

s12016-016-8558-3. PMID: 27273086.

Leite MI, Ströbel P, Jones M, et al. Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Ann Neurol. 2005 Mar;57(3):444-8. doi: 10.1002/

ana.20386. PMID: 15732104.

Klein L, Kyewski B, Allen PM, et al. Positive and negative selection of the T cell repertoire: what thymocytes see (and don't see). Nat Rev Immunol. 2014 Jun;14(6):377-91. doi: 10.1038/nri3667. Epub 2014 May 16. PMID: 24830344; PMCID: PMC4757912.

Anderson MS, Venanzi ES, Klein L, et al. Projection of an immunological self shadow within the thymus by the aire protein. Science. 2002 Nov 15;298(5597):1395-401. doi: 10.1126/science.1075958. Epub 2002 Oct 10. PMID: 12376594.

Le Panse R, Bismuth J, Cizeron-Clairac G, et al. Thymic remodeling associated with hyperplasia in myasthenia gravis. Autoimmunity. 2010 Aug;43(5-6):401-12. doi: 10.3109/

08916930903563491. PMID: 20402580.

Shiono H, Wong YL, Matthews I, et al. Spontaneous production of anti-IFN-alpha and anti-IL-12 autoantibodies by thymoma cells from myasthenia gravis patients suggests autoimmunization in the tumor. Int Immunol. 2003 Aug;15(8):903-13. doi: 10.1093/intimm/dxg088. PMID: 12882828.

Deymeer F. Nöromuskuler Kavşak Hastalıkları, Emre M (Ed.), Temel Nöroloji içinde. Güneş Tıp Kitabevi; 2013. p. 426-439

Cron MA, Maillard S, Villegas J, et al. Thymus involvement in early-onset myasthenia gravis. Ann N Y Acad Sci. 2018 Jan;1412(1):137-145. doi: 10.1111/nyas.13519. Epub 2017 Nov 10. PMID: 29125185.

Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. J Clin Invest. 2006 Nov;116(11):2843-54. doi: 10.1172/JCI29894. PMID: 17080188; PMCID: PMC1626141.

Lang B, Vincent A. Autoimmune disorders of the neuromuscular junction. Curr Opin Pharmacol. 2009 Jun;9(3):336-40. doi: 10.1016/j.coph.2009.04.005. Epub 2009 May 8. PMID: 19428298.

Willcox N, Leite MI, Kadota Y, et al. Autoimmunizing mechanisms in thymoma and thymus. Ann N Y Acad Sci. 2008;1132:163-73. doi: 10.1196/annals.1405.021. PMID: 18567866.

Poëa-Guyon S, Christadoss P, Le Panse R, et al. Effects of cytokines on acetylcholine receptor expression: implications for myasthenia gravis. J Immunol. 2005 May 15;174

(10):5941-9. doi: 10.4049/jimmunol.174.10.5941. PMID: 15879086.

Le Panse R, Bismuth J, Cizeron-Clairac G, et al. Thymic remodeling associated with hyperplasia in myasthenia gravis. Autoimmunity. 2010 Aug;43(5-6):401-12. doi: 10.3109

/08916930903563491. PMID: 20402580.

Cufi P, Dragin N, Ruhlmann N, et al. Central role of interferon-beta in thymic events leading to myasthenia gravis. J Autoimmun. 2014 Aug;52:44-52. doi: 10.1016/j.jaut.

2013.12.016. Epub 2014 Jan 3. PMID: 24393484.

Oflazer P, Deymeer F. Bölüm 37: Kas ve nöromüsküler kavşak hastalıkları.Öge E, Baykan B. Nöroloji, 2.baskı. İstanbul; 2011:729-771.

Merigglioli MN. Myastenia Gravis:Immunopathogenesis, diagnosis, and management. Contınuum 2009;15(1):35-62.

Bershad EM, Feen ES, Suarez JI. Myasthenia gravis crisis. South Med J. 2008 Jan;101

(1):63-9. doi: 10.1097/SMJ.0b013e31815d4398. PMID: 18176295.

Evoli A, Tonali PA, Padua L, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain. 2003 Oct;126(Pt 10):2304-11. doi: 10.1093/brain/awg223. Epub 2003 Jun 23. PMID: 12821509.

Pascuzzi RM. The edrophonium test. Semin Neurol. 2003 Mar;23(1):83-8. doi: 10.1055/

s-2003-40755. PMID: 12870109.

Hatanaka Y, Claussen GC, Oh SJ. Anticholinesterase hypersensitivity or intolerance is comman inMuSK antibody positive myasthenia gravis. Neurology 2005;64:79.

Oger J, Frykman H. An update on laboratory diagnosis in myasthenia gravis. Clin Chim Acta. 2015 Sep 20;449:43-8. doi: 10.1016/j.cca.2015.07.030. Epub 2015 Aug 1. PMID: 26238187.

Yamamoto D, Imai T, Tsuda E, et al. Effect of local cooling on excitation-contraction coupling in myasthenic muscle: Another mechanism of ice-pack test in myasthenia gravis. Clin Neurophysiol. 2017 Nov;128(11):2309-2317. doi: 10.1016/j.clinph.2017.08.030. Epub 2017 Sep 22. PMID: 29040921.

Phillips WD, Vincent A. Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms. F1000Res. 2016 Jun 27;5:F1000 Faculty Rev-1513. doi: 10.12688/f1000research.8206.1. PMID: 27408701; PMCID: PMC4926737.

Guptill JT, Sanders DB, Evoli A. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve. 2011 Jul;44(1):36-40.doi: 10.1002/mus.22006. PMID: 21674519.

Benatar M. A systematic review of diagnostic studies in myasthenia gravis. Neuromuscul Disord. 2006 Jul;16(7):459-67. doi: 10.1016/j.nmd.2006.05.006. Epub 2006 Jun 21. PMID: 16793269.

Padua L, Caliandro P, Di Iasi G, et al. Reliability of SFEMG in diagnosing myasthenia gravis: sensitivity and specificity calculated on 100 prospective cases. Clin Neurophysiol. 2014 Jun;125(6):1270-3. doi: 10.1016/j.clinph.2013.11.005. Epub 2013 Nov 15. PMID: 24296278.

Martin TJ. Horner Syndrome: A Clinical Review. ACS Chem Neurosci. 2018 Feb 21;9(2):177-186. doi: 10.1021/acschemneuro.7b00405. Epub 2017 Dec 20. PMID: 29260849.

Güleç R, Koç F. Mitokondriyal kas hastalıkları. Taşdemir N, editör. Kas Hastalıkları. 1. Baskı. Ankara: Türkiye Klinikleri; 2020. p.49- 59.

Deymeer. F. Turkiye Klinikleri J Neurol-Special Topics. 2011;4(2):110-6

Şirin NG, Tanrıdağ T. Lambert-Eaton miyastenik sendrom. Tanrıdağ T, editör.

Nöromusküler Kavşak Hastalıkları. 1. Baskı. Ankara: Türkiye Klinikleri; 2019. p.44-9.

Lázaro E, Amayra I, López-Paz JF, et al. Facial affect recognition in myasthenia gravis.

Span J Psychol. 2013;16:E52. doi: 10.1017/sjp.2013.59. PMID: 23866249.

Kulaksizoglu IB. Mood and anxiety disorders in patients with myasthenia gravis:

aetiology, diagnosis and treatment. CNS Drugs. 2007;21(6):473-81. doi:

10.2165/00023210-200721060-00004. PMID: 17521227.

Gilhus NE, Andersen H, Andersen LK, et al. Generalized myasthenia gravis with acetylcholine receptor antibodies: A guidance for treatment. Eur J Neurol 2024; 31:e16229. Hehir MK 2nd, Li Y. Diagnosis and Management of Myasthenia Gravis. Continuum (Minneap Minn) 2022; 28:1615.

Hehir MK 2nd, Li Y. Diagnosis and Management of Myasthenia Gravis. Continuum (Minneap Minn) 2022; 28:1615.

Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for

management of myasthenia gravis: Executive summary. Neurology 2016; 87:419.

Punga AR, Stålberg E. Acetylcholinesterase inhibitors in MG: to be or not to be? Muscle Nerve 2009; 39:724.

Mehndiratta MM, Pandey S, Kuntzer T. Acetylcholinesterase inhibitor treatment for myasthenia gravis. Cochrane Database Syst Rev 2014; :CD006986.

Nicolle MW. Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome. Continuum (Minneap Minn) 2016; 22:1978.

Liu GT, Volpe NJ, Galetta SL. Eyelid and facial nerve disorders. In: Neuro-Ophthalmology, Liu GT, Volpe NJ, Galetta SL (Eds), WB Saunders, Philadelphia 2001. p.496.

Gajdos P, Chevret S, Toyka K. Plasma exchange for myasthenia gravis. Cochrane

Database Syst Rev 2002; :CD002275.

Ebadi H, Barth D, Bril V. Safety of plasma exchange therapy in patients with myasthenia gravis. Muscle Nerve 2013; 47:510.

Barth D, Nabavi Nouri M, Ng E, et al. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology 2011; 76:2017.

Gajdos P, Chevret S, Toyka KV. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev 2012; 12:CD002277.

Patwa HS, Chaudhry V, Katzberg H, et al. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2012; 78:1009.

Manolopoulos A, Alzuabi M, Elmashala A, et al. Immunoglobulin for myasthenia gravis.

Cochrane Database Syst Rev 2025; 10:CD013801.

Arsura E, Brunner NG, Namba T, Grob D. High-dose intravenous methylprednisolone in myasthenia gravis. Arch Neurol 1985; 42:1149.

Lindberg C, Andersen O, Lefvert AK. Treatment of myasthenia gravis with

methylprednisolone pulse: a double blind study. Acta Neurol Scand 1998; 97:370.

Lacomis D. Myasthenic crisis. Neurocrit Care 2005; 3:189.

Narayanaswami P, Sanders DB, Wolfe G, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology 2021; 96:114.

Rivner MH, Quarles BM, Pan JX, et al. Clinical features of LRP4/agrin-antibody-positive

myasthenia gravis: A multicenter study. Muscle Nerve 2020; 62:333.

Ionita CM, Acsadi G. Management of juvenile myasthenia gravis. Pediatr Neurol 2013; 48:95.

Chiang LM, Darras BT, Kang PB. Juvenile myasthenia gravis. Muscle Nerve 2009; 39:423.

Andrews PI. Autoimmune myasthenia gravis in childhood. Semin Neurol 2004; 24:101.

Tracy MM, McRae W, Millichap JG. Graded response to thymectomy in children with myasthenia gravis. J Child Neurol 2009; 24:454.

Kolski H, Vajsar J, Kim PC. Thoracoscopic thymectomy in juvenile myasthenia gravis. J Pediatr Surg 2000; 35:768.